Theragenics Corporation (NYSE: TGX), a medical device company serving
the surgical products and prostate cancer treatment markets, today
announced that it has entered into a Second Amended and Restated Credit
Agreement with Wells Fargo Bank, National Association. The new three
year credit agreement, which is unsecured, replaces the $30 million
credit agreement with Wells Fargo that was set to expire on October 31,
2012. Borrowings of $22 million that were outstanding under the old
credit agreement have been refinanced under the new $40 million credit
agreement. The interest rate on outstanding borrowings under the new
credit agreement has been reduced from LIBOR plus 2.25% to LIBOR plus
1.75%. The financial covenants in the new credit agreement are
substantially similar to the previous credit agreement.
"Obtaining our new credit agreement is a significant accomplishment,"
stated M. Christine Jacobs, Chairman and Chief Executive Officer of
Theragenics. "We believe that the increase in the available credit and
the lower interest rate, in the current credit environment, is
attributable to our strategy, our focus on cash flows and the strength
of our balance sheet. With this new credit agreement in place we can
continue to focus on our strategy of growth and diversification."
Under the new amended and restated credit agreement, the $40 million
revolving line of credit matures on October 10, 2015, with interest
payable at LIBOR plus 1.75%. $22 million in revolving loans are
currently outstanding under this revolving line of credit. The new
credit agreement is unsecured but provides for a lien to be established
on substantially all assets of the Company if certain events of default
occur. Provisions of the new credit facility require the Company to
maintain a minimum cash and investment balance, as defined in the
agreement, of $10 million. The terms also require the maintenance of
certain minimum financial covenants, including a minimum fixed charge
coverage ratio and a maximum debt to tangible net worth.